Avidity biosciences partners with the fshd society to raise awareness of facioscapulohumeral muscular dystrophy on world fshd day

Fshd society to host avidity webinar on positive initial data from the phase 1/2 fortitude™ trial for people living with fshd today at 1:00 p.m. et san diego , june 20, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced it is partnering with the fshd society and joining the global community of patients, caregivers, and healthcare providers to raise awareness of facioscapulohumeral muscular dystrophy in support of world fshd day.
RNA Ratings Summary
RNA Quant Ranking